The stock of Eton Pharmaceuticals Inc. (NASDAQ:ETON) increased by $0.36 on Tuesday to $4.40, up 8.91 percent. The last five days have seen an average of 3,588,379 shares of common stock traded. 16 times new highs were reached in the current year, with a gain of $1.50. The average number of shares traded over the last 20 days was 936,120, while the average volume over the last 50 days totaled 410,692.
ETON stock appreciated 47.15% since last month. On 07/31/23, the company’s shares reached a one-month low of $2.42. The stock touched a high of $4.28 on 08/15/23, after rallying from a low of $1.95 in 52 weeks. The price of ETON stock has risen by 56.02% or $1.50 this year, reaching a new high 16 times. Still, the stock price is up 2.80% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ETON stock investors should be aware that Eton Pharmaceuticals Inc. (ETON) stock had its last reported insider trading activity 327 days ago on Sep 22. On Sep 22, Chief Executive Officer BRYNJELSEN SEAN acquired 10,000 shares at $2.10 each. This transaction resulted in the insider spending $21,042.
Valuation Metrics
Beta for the stock is 1.26. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.33, the price-to-book (PB) ratio of 10.00, and the price-to-cash flow ratio of 40.63.
Financial Health
For the three months ended June 29, Eton Pharmaceuticals Inc.’s quick ratio was 2.50, while its current ratio was 2.60, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.46, and the total debt to equity ratio is 0.57. As far as profitability goes, gross margin for the trailing twelve months is 67.00% percent. Eton Pharmaceuticals Inc.’s EBITDA margin for the year ended June 29 was -30.56%, whereas its operating margin stood at -47.20% for the same period. Based on annual data, it had gross profit of $14.32 million and revenue of $21.25 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ETON’s return on assets (ROA) during the last 12 months has been -38.60%. There was a -44.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -74.00%.
Earnings Surprise
According to Eton Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $11.68 million, while revenues rose by 36.99% to $5.3 million. It was predicted that Eton Pharmaceuticals Inc.’s quarterly earnings would be $0.18, but it ended up being -$0.09. EBITDA was $4.13 million for the quarter. At the end of Eton Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 14.21 million, while its total debt was $6.24 million. Equity owned by shareholders amounts to $25.65 million.
Technical Picture
Here’s a quick look at Eton Pharmaceuticals Inc.’s (ETON) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 82.71%, suggesting the stock is Overbought, with a 175.58% historical volatility rate.
The stochastic %K and %D were 96.81% and 75.32% respectively, while the average true range (ATR) was 0.32. Based on the 14-day stochastic reading of 98.45%, the RSI (14) reading is 74.55%. On the 9-day MACD Oscillator, the stock is at 0.90, and the 14-day reading is at 1.02.
Analyst Ratings
Analysts have assigned Eton Pharmaceuticals Inc. (ETON) an Buy rating. ETON is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is ETON’s price target for the next 12 months?
The current consensus forecast for the stock is between $10.00 and $10.00, with a median target price of $10.00. In analyzing these forecasts, the average price target given by analysts for Eton Pharmaceuticals Inc. (ETON) is $10.00.
